The DOI matches its Crossref record, with a small difference in title or year; 26 of the 26 references it cites were found in a registry or an index.
Tocilizumab for the management of immune mediated adverse events secondary to PD-1 blockade
Abstract
BACKGROUND: Immune checkpoint inhibitors are poised to revolutionize the management of a growing number of malignancies. Unfortunately, the management of steroid-refractory immune mediated adverse events is based on a paucity of randomized data and limited to single center experiences. Our initial experience with the IL-6 receptor antagonist tocilizumab showed clinical improvement in a wide variety of irAEs. As a result, we adopted the use of tocilizumab for the management of steroid refractory irAEs. METHODS: The character and clinical course of irAEs were abstracted from the medical record and analyzed. The dose of tocilizumab was 4 mg/kg given IV over one hour. C-reactive protein was drawn at first nivolumab infusion and at q two weeks (and with irAEs) thereafter. Clinical improvement was defined as either: documentation of resolution of symptoms or hospital discharge within seven days. RESULTS: Of the initial 87 patients that were treated with nivolumab, 34 required tocilizumab (39.1%). All patients were on corticosteroids. The majority (88.2%) were lung cancer patients. The index grade 3/4 irAE was pneumonitis in 35.3%, serum sickness/SIRS in 35.3%, cerebritis in 14.7% and one case each of hypophysitis, colitis, pancreatitis, hepatitis and immune mediated coagulopathy. Median time between first nivolumab and initiation of tocilizumab was 76 days (range 1-429). There was a statistically significant increase in C-reactive protein from a median of 23 mg/L (range 0.1-238.5) at baseline to 109.3 mg/L (21.5-350.4) at the time of index irAE, followed by a decrease to 19.2 mg/L (0.25-149) after tocilizumab ( p < 0.00001). Clinical improvement was noted in 27/34 patients (79.4%). Some patients (52.9%) required a single dose, while 38.2% required two, 8.8% required three and 1 patient required four doses. Twenty-seven doses were given in the inpatient setting (49.1%). Median time to discharge was four days (range 1-27). Seventy-four percent of patients were discharged home. For the 53 doses of tocilizumab that were delivered when infliximab was an option, there was a cost savings of $141,048.72 (WAC) during the 18 month study period. CONCLUSIONS: Tocilizumab may be a therapeutic option for the management of steroid refractory irAEs secondary to immune checkpoint blockade. However, randomized trials are needed to better elucidate the relative efficacy and safety of these agents.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, it was demonstrated that TCZ may be used as a second-line therapy for irAEs and for steroid-refractory irAEs; clinical improvement was observed in 79.4% of patients, with 52.9% of patients requiring only a single dose for a symptomatic response.59”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [59]
Citations
Cites
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
The pro- and anti-inflammatory properties of the cytokine interleukin-6
Scheller, J., Chalaris, A., Schmidt-Arras, D., & Rose-John, S. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2011.01.034 · Cited by 3,212
Current concepts in the diagnosis and management of cytokine release syndrome.
Lee, D. W., Gardner, R., Porter, D. L., Louis, C. U., Ahmed, N., Jensen, M., Grupp, S. A., & Mackall, C. L. (2014) · Blood · doi:10.1182/blood-2014-05-552729 · Cited by 2,806
Efficacy and Toxicity Management of 19-28z CAR T Cell Therapy in B Cell Acute Lymphoblastic Leukemia
Davila, M. L., Rivière, I., Wang, X., Bartido, S. M., Park, J. H., Curran, K. J., Chung, S. S., Stefanski, J., Bórquez-Ojeda, O., Olszewska, M., et al. (2014) · Science Translational Medicine · doi:10.1126/scitranslmed.3008226 · Cited by 2,514
Immune-related adverse events with immune checkpoint blockade: a comprehensive review
Michot, J. M., Bigenwald, C., Champiat, S., Collins, M., Carbonnel, F., Postel-Vinay, S., Berdelou, A., Varga, A., Bahleda, R., Hollebecque, A., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2015.11.016 · Cited by 2,127
Cetuximab-Induced Anaphylaxis and IgE Specific for Galactose-α-1,3-Galactose
Chung, C. H., Mirakhur, B., Chan, E., Le, Q.-T., Berlin, J., Morse, M., Murphy, B. A., Satinover, S. M., Hosen, J., Mauro, D., et al. (2008) · New England Journal of Medicine · doi:10.1056/nejmoa074943 · Cited by 1,521
Toxicities of chimeric antigen receptor T cells: recognition and management
Brudno, J. N., & Kochenderfer, J. N. (2016) · Blood · doi:10.1182/blood-2016-04-703751 · Cited by 1,283
Research works printed but not linked: 4
- Haratani K, JAMA Oncol
- Shoushtari AN, JAMA Oncol
- 10.1093/annonc/mdv623 · DOI · Paper page
- Kim N, 2015, Oncology Letters, 9
Cited by
Sorted by citations
Items 201–300 of 330
Co Treatment With Biologic Agents and Immunotherapy in the Setting of irAEs of Difficult Management
Robles, V., Martínez‐Valle, F., & Borruel, N. (2022) · Frontiers in Medicine · doi:10.3389/fmed.2022.906098 · Cited by 9
Autoimmune and autoinflammatory manifestations in inborn errors of immunity
Kačar, M., Markelj, G., & Avčin, T. (2022) · Current Opinion in Allergy and Clinical Immunology · doi:10.1097/aci.0000000000000860 · Cited by 8
Nikoo, M., Hassan, Z. F., Mardasi, M., Rostamnezhad, E., Roozbahani, F., Rahimi, S., & Mohammadi, J. (2023) · Pathology - Research and Practice · doi:10.1016/j.prp.2023.154473 · Cited by 9
Özlük, A. A., Günenç, D., Yildirim, S. S., & Karaca, B. (2024) · Melanoma Research · doi:10.1097/cmr.0000000000000969 · Cited by 9
McCallen, J., Naqash, A. R., Marie, M. A., Atwell, D. C., Muzaffar, M., Sharma, N. J., Amara, S., Liles, D., Walker, P. R., & Yang, L. V. (2021) · Acta Oncologica · doi:10.1080/0284186x.2021.1917001 · Cited by 9
Self-citationZheng, L., Yang, X., Wei, Y., You, J., Li, H., Liao, J., & Cheng, Y. (2022) · Materials & Design · doi:10.1016/j.matdes.2022.110738 · Cited by 9
Miao, K., & Zhang, L. (2022) · Cancer Pathogenesis and Therapy · doi:10.1016/j.cpt.2022.11.003 · Cited by 8
Ploch, M., Zhao, S., Wei, L., Englert, J. A., Cohen, S. P., Inks, M., Meara, A. S., Fussner, L. A., Owen, D. H., & Ho, K. (2025) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-024-03902-3 · Cited by 8
Hadfield, M. J., Merkin, R. D., Rouhani, S. J., & Reynolds, K. L. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101625 · Cited by 8
Expert consensus on cancer treatment-related lung injury
Lin, X., Guo, H., Zhao, W., Li, M., Lin, G., Chu, Q., Chen, E., Chen, L., Chen, R., Chu, T., et al. (2025) · Journal of Thoracic Disease · doi:10.21037/jtd-2025-292 · Cited by 8
Nagpal, C., Rastogi, S., Shamim, S. A., & Prakash, S. (2023) · ecancermedicalscience · doi:10.3332/ecancer.2023.1644 · Cited by 8
Moodabagil, M., Easterling, R. S., Peng, J., Abu‐Sbeih, H., Meara, A. S., Donnelly, E. F., Owen, D. H., & Ho, K. (2024) · The Oncologist · doi:10.1093/oncolo/oyae147 · Cited by 8
Immune Checkpoint Inhibitors in Cancer Treatment and Incidence of Pancreatitis
Nwankwo, O. C., Lara-Salazar, F. M., Lara-Salazar, S., Abdulrahim, A. O., Chijioke, I., Singh, J., Koradia, I., Gomez, N. M., Prakash, R., Gopagoni, R., et al. (2024) · Cureus · doi:10.7759/cureus.68043 · Cited by 8
Strouse, J., Chan, K. K., Baccile, R., He, G., Louden, D. N., Giurcanu, M. C., Singh, A., Rieth, J. M., Abdel‐Wahab, N., Katsumoto, T. R., et al. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1499478 · Cited by 9
Expert Consensus for Treating Cancer Patients During the Pandemic of SARS-CoV-2
Dong, S., Luo, C., Hu, X., Zhang, J., Cai, Q., Yu, Q., Ran, F., Ou, W., Wang, J., Huang, Q., et al. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.01555 · Cited by 8
Management of Immune-Related Adverse Events in Patients With Non-Small Cell Lung Cancer
Burke, M., & Rashdan, S. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.720759 · Cited by 9
Chan, K. K., & Bass, A. R. (2024) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2024.02.007 · Cited by 7
Treatment of steroid‐resistant checkpoint inhibitor pneumonitis with pirfenidone: A case report
Miao, K., Xu, Y., Xu, W., Zhang, Y., Xu, Y., Tian, X., & Zhang, L. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.13921 · Cited by 7
Matsumoto, K., Shiroyama, T., Kuge, T., Miyake, K., Yamamoto, Y., Yoneda, M., Yamamoto, M., Naito, Y., Suga, Y., Fukushima, K., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-162 · Cited by 7
Yin, N., Liu, X., Ye, X., Song, W., Lu, J., & Chen, X. (2022) · Frontiers in Oncology · doi:10.3389/fonc.2022.961266 · Cited by 7
Riveiro‐Barciela, M., Soler, M. J., Barreira‐Díaz, A., Bermejo, S., Bruera, S., & Suarez-Almazor, M. E. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11205977 · Cited by 7
Zhou, M.-H., Ye, M., Zhang, Z., Tao, F., & Zhang, Y. (2024) · World Journal of Clinical Cases · doi:10.12998/wjcc.v12.i18.3555 · Cited by 7
Poveda, J. J. R., Herrera, M., Huizi, J. J. Z., Sellarés, J., & Hernández‐González, F. (2026) · Pulmonary Therapy · doi:10.1007/s41030-025-00338-7 · Cited by 6
Falade, A. S., Zubiri, L., Wu, C., Perlman, K., Sun, J., Hathaway, N., Grealish, K., Lopiccolo, J., Reynolds, K. L., & Mooradian, M. J. (2024) · The Oncologist · doi:10.1093/oncolo/oyae189 · Cited by 6
Brown, A. C., Quiroz, J., Parikh, D. A., Li, Y., Ritzer, L., Rosen, R. B., & Deobhakta, A. A. (2024) · BMC Ophthalmology · doi:10.1186/s12886-024-03575-7 · Cited by 7
Acquired resistance to PD-L1 inhibition enhances a type I IFN-regulated secretory program in tumors
Shi, Y., McKenery, A., Dolan, M., Mastri, M., Hill, J. W., Dommer, A. P., Benzekry, S., Long, M., Abrams, S. I., Puzanov, I. J., et al. (2024) · EMBO Reports · doi:10.1038/s44319-024-00333-0 · Cited by 8
Fu, Y., Zeng, C. H., An, C., Liu, Y., Shin, J. H., & Li, X. (2023) · Cancers · doi:10.3390/cancers15041324 · Cited by 6
Sato, K., Inoue, J., Ninomiya, M., Iwata, T., Sano, A., Tsuruoka, M., Onuki, M., Sawahashi, S., Ouchi, K., & Masamune, A. (2023) · Clinical Journal of Gastroenterology · doi:10.1007/s12328-023-01832-8 · Cited by 6
Neurologic manifestations of autoimmunity with immune checkpoint inhibitors
McCombe, J. A., Sechi, E., & Ζεκερίδου, Α. (2024) · Handbook of clinical neurology · doi:10.1016/b978-0-12-823912-4.00024-4 · Cited by 6
Testing Immune-Related Adverse Events in Cancer Immunotherapy
Farmer, J. R. (2019) · Clinics in Laboratory Medicine · doi:10.1016/j.cll.2019.07.012 · Cited by 6
Wang, H., Guo, X., Zhou, J., Duan, L., Si, X., Zhang, L., Li, Y., Liu, X., Wang, M., Shi, J., et al. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.10.03 · Cited by 6
Les limites des inhibiteurs de points de contrôle immunitaire et la gestion de leur toxicité
Kostine, M., Marabelle, A., Schaeverbeke, T., & Kfoury, M. (2019) · médecine/sciences · doi:10.1051/medsci/2019191 · Cited by 6
Berzero, G., Pïcca, A., & Psimaras, D. (2020) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000681 · Cited by 6
Revisiting immunogenic cell death to improve treatment response in cancer
Shakfa, N. E., Siemens, D. R., & Koti, M. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821310-0.00008-5 · Cited by 6
Li, Z., Zheng, X., Xia, H., 陆龙, Chen, X., Chen, Y., Wu, J., Shi, Y., & Wu, C. (2026) · Cell Death and Disease · doi:10.1038/s41419-026-08440-7 · Cited by 5
Treatment of Myositis Associated With Immune Checkpoint Inhibitors
Matas-García, A., Martínez‐Hernández, E., & Milisenda, J. C. (2023) · Current Treatment Options in Rheumatology · doi:10.1007/s40674-023-00212-0 · Cited by 5
Hepatobiliary complications of immune checkpoint inhibitors in cancer
Zhuang, D., Zhang, D. E. W., & Riordan, S. M. (2024) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2024.00257 · Cited by 5
Pulmonary Toxicities of Immune Check Point Inhibitors in the Management of Cancer: Mini Review
Jayakrishnan, B., Al-Moundhri, M. S., Burney, I. A., Al-Hashami, Z. S., & Al-Baimani, K. S. (2022) · Advances in respiratory medicine · doi:10.5603/arm.84782 · Cited by 5
Characteristics of Immune Checkpoint Inhibitor-Induced Colitis: A Systematic Review
Nakane, T., Mitsuyama, K., Yamauchi, R., Kakuma, T., & Torimura, T. (2021) · The Kurume Medical Journal · doi:10.2739/kurumemedj.ms682006 · Cited by 5
Rose, N., Furer, V., Polachek, A., Elkayam, O., & Gertel, S. (2024) · European Journal of Rheumatology · doi:10.5152/eurjrheum.2024.23091 · Cited by 5
Mechanism and Management of Checkpoint Inhibitor-Related Toxicities in Genitourinary Cancers
Li, H., Sahu, K. K., & Maughan, B. L. (2022) · Cancers · doi:10.3390/cancers14102460 · Cited by 6
Ascierto, P. A., Agarwala, S. S., Warner, A. B., Ernstoff, M. S., Fox, B. A., Gajewski, T. F., Galon, J., Garbe, C., Gastman, B., Gershenwald, J. E., et al. (2023) · Journal of Translational Medicine · doi:10.1186/s12967-023-04325-x · Cited by 5
Diffuse pneumonitis from coronavirus HKU1 on checkpoint inhibitor therapy
Serzan, M. T., Kumar, P. N., & Atkins, M. B. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000898 · Cited by 5
Ma, X., Chen, J., Chen, S., Lan, X., Wei, Z., Gao, H., & Hou, E. (2024) · Medicine · doi:10.1097/md.0000000000038991 · Cited by 4
Checkpoint inhibitor pneumonitis: Short review of literature and case report
Wass, R. E., Lang, D., Horner, A., & Lamprecht, B. (2021) · memo - Magazine of European Medical Oncology · doi:10.1007/s12254-021-00756-8 · Cited by 4
Su, A., Pedraza, R., & Kennecke, H. F. (2023) · Current Oncology · doi:10.3390/curroncol30040279 · Cited by 4
Shifting From a “One Size Fits All” to a Tailored Approach for Immune-Related Adverse Events
Ferrara, R., Campochiaro, C., & Garassino, M. C. (2021) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2020.11.029 · Cited by 4
Chen, I. M., Donia, M., Chamberlain, C. A., Jensen, A. W. P., Draghi, A., Theile, S., Madsen, K. S., Hasselby, J. P., Toxværd, A., Høgdall, E. V. S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4165619 · Cited by 4
Gao, J., Miao, J., Zhinan, C., & Zhu, P. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1611692 · Cited by 4
Cai, Y., & Ni, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1757711 · Cited by 3
Hou, J., Mu, G., Zhang, Z., Xiang, Q., & Cui, Y. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-026-04380-5 · Cited by 4
Sarvilina, I. V., Lila, A. M., Громова, О. А., Torshin, I. Y., Shavlovskaya, O. A., & Александровна, Т. Е. (2022) · Modern Rheumatology Journal · doi:10.14412/1996-7012-2022-2-92-98 · Cited by 3
Chen, Y. J., Zeng, Y., Zhang, K., Lal, N., Zhao, Y., Qi, F., & Zhang, T. (2025) · Thoracic Cancer · doi:10.1111/1759-7714.70184 · Cited by 3
The “Heater” of “Cold” Tumors–Blocking IL‐6
Pu, W., Ma, C., Wang, B., Zhu, W., & Chen, H. (2024) · Advanced Biology · doi:10.1002/adbi.202300587 · Cited by 5
Releasing the brakes: the role of immune checkpoint inhibitors in laryngeal cancer
Athanasopoulos, M., Samara, P., Agrogiannis, G. D., Athanasopoulos, I., Kavantzas, N., Kyrodimos, E., & MASTRONIKOLIS, N. S. (2025) · Exploration of Targeted Anti-tumor Therapy · doi:10.37349/etat.2025.1002292 · Cited by 3
Advances in mechanistic investigation and treatment of steroid-refractory ICI-induced liver injury
Hu, H., Shen, X., & Chen, J. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01721-z · Cited by 2
Yu, J., Liu, X. H., Ma, X., Li, L., Liu, Y., Yin, W., Li, Q., Cao, B., & Liu, W. (2025) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s534323 · Cited by 2
Circulating Biomarkers in the Detection of Cardiovascular Toxicity
Stankovic, S. D., Radisavljevic, N. M., Bajić, Z., Polovina, M. M., & Djuric, D. M. (2025) · Advances in biochemistry in health and disease · doi:10.1007/978-3-031-90598-8_32 · Cited by 2
Pulmonary toxicity of immune-checkpoint inhibitors
Mahiat, C., Cadranel, J. L., Fallet, V., Méteyé, C., Gendarme, S., Slomka, J., & Canellas, A. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104329 · Cited by 2
Pilia, M. F., Felip, E., Espejo, D., Pardo, N., Casas, M., Clofent, D., Villar, A., & Ojanguren, Í. (2026) · Open Respiratory Archives · doi:10.1016/j.opresp.2026.100578 · Cited by 2
Mehta, R., & Jayakumar, I. (2026) · JOURNAL OF PEDIATRIC CRITICAL CARE · doi:10.4103/jpcc.jpcc_138_25 · Cited by 2
Immune Checkpoint Inhibitor–Associated Acute Kidney Injury
Gupta, S., Fenoglio, R., Murakami, N., Sharon, E., Herrmann, S. M., Workeneh, B., Roccatello, D., Blau, J. A., Ostermann, M., Ronco, C., et al. (2026) · Journal of the American Society of Nephrology · doi:10.1681/asn.0000001232 · Cited by 2
Hepatology (Liver and Bile Duct)
Zhang, H. C., Wang, L. S., & Miller, E. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_7 · Cited by 2
Cytokine Response to Nanoparticles Bearing Nucleic Acid Cargo
Sundaram, D. N. M., Nasrullah, M., & Uludağ, H. (2023) · Studies in mechanobiology, tissue engineering and biomaterials · doi:10.1007/978-981-99-6564-9_10 · Cited by 2
Spencer, K. R., Singer, E. A., & Girda, E. (2021) · Journal of Cancer Biology · doi:10.46439/cancerbiology.2.029 · Cited by 2
Calabrese, L. H., & Calabrese, C. M. (2020) · Current Opinion in Rheumatology · doi:10.1097/bor.0000000000000684 · Cited by 2
Song, P., Wang, H., Si, X., Guo, X., Li, Y., Zhou, J., Duan, L., Zhang, L., & Wang, M. (2020) · Thoracic Cancer · doi:10.1111/1759-7714.13553 · Cited by 2
Wilde, R. D., Saerens, M., Hoorens, A., Geerts, A. M., & Jacobs, C. (2023) · International Journal of Translational Medicine · doi:10.3390/ijtm3030019 · Cited by 2
Valiev, T. T., Zakharova, E. V., Ignatenko, O. A., Батманова, Н. А., Михайлова, Е. В., Киргизов, К. И., & Варфоломеева, С. Р. (2020) · Russian Journal of Pediatric Hematology and Oncology · doi:10.21682/2311-1267-2020-7-3-104-111 · Cited by 2
Use of Tocilizumab in Management of Post-Operative Myelomonocytic Leukemoid Reaction
Melody, M. E., Butts, E., Menke, D. M., Landolfo, K. P., Oken, K. R., Sher, T., & Khurana, S. (2020) · Leukemia Research Reports · doi:10.1016/j.lrr.2020.100228 · Cited by 2
Kowalski, B., Valaperti, A., Steiner, U. C., Scholtze, D., Wieser, S., Eisenring, M., Widmer, A., Bezel, P., Kohler, M., & Franzen, D. (2020) · Research Square · doi:10.21203/rs.3.rs-129954/v1 · Cited by 2
Chen, I. M., Donia, M., Chamberlain, C. A., Jensen, A. W. P., Draghi, A., Theile, S., Madsen, K. S., Hasselby, J. P., Toxværd, A., Høgdall, E. V. S., et al. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4176353 · Cited by 2
Immunotherapy: remember the host
Walker, P. R. (2023) · Translational Lung Cancer Research · doi:10.21037/tlcr-23-743 · Cited by 2
Self-citationNalabothu, R., & Johnson, D. B. (2025) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2025.2599891 · Cited by 1
Liu, S., Zhang, Y., Guan, Y., Xie, H., Dong, Y., Chang, J., Xie, Q., Wang, B., & Wang, J. (2026) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-025-04287-7 · Cited by 1
Xu, W., Cao, B., & Li, X. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1728047 · Cited by 1
Neurological immune-related adverse events of immune-checkpoint inhibitors: an updated review
Pïcca, A., & Psimaras, D. (2026) · La Presse Médicale · doi:10.1016/j.lpm.2026.104341 · Cited by 1
Rabin, B., Li, M., Sack, J., Benque, I. J., & Zucker, S. D. (2026) · Hepatology Communications · doi:10.1097/hc9.0000000000000922 · Cited by 1
Pulmonary toxicity of immune checkpoint inhibitors
Garvey, S., & Nadarajan, P. (2026) · Breathe · doi:10.1183/20734735.0276-2025 · Cited by 1
Immune-related Pulmonary Toxicity From Cancer Immunotherapy: A Systematic Approach
Thiruchelvam, N., Rajasurya, V., Tharmendira, S., Torbic, H., Waldron, M., Stoller, J. K., & Culver, D. A. (2020) · Clinical Pulmonary Medicine · doi:10.1097/cpm.0000000000000383 · Cited by 1
Green, H. E., & Nieva, J. J. (2021) · Journal of Investigative Medicine · doi:10.1136/jim-2021-001806 · Cited by 1
Xu, S., Miura, K., Shukuya, T., Harada, S., Fujioka, M., Winardi, W., Shimamura, S., Kurokawa, K., Sumiyoshi, I., Miyawaki, T., et al. (2023) · Cancers · doi:10.3390/cancers15041170 · Cited by 1
Navigating the waters of immune checkpoint inhibitor pulmonary toxicity
Puthumana, R. M., Vehar, S. J., & Koch, A. L. (2025) · Journal of Precision Respiratory Medicine · doi:10.2500/jprm.2025.8.240015 · Cited by 1
Wang, H., Song, P., Si, X., Guo, X., Li, Y., Zhou, J., Duan, L., Zhang, L., Wang, M., & Zhang, L. (2019) · PubMed Central · doi:10.3779/j.issn.1009-3419.2019.10.01 · Cited by 1
Саржевский, В. О., Андреевна, Д. Е., Mochkin, N. E., Спорник, А. А., Мамедова, А. А., Smirnova, E. G., Bannikova, A. E., Samoilova, A. R., Сергеевич, Б. В., Бронов, О. Ю., et al. (2020) · Clinical oncohematology · doi:10.21320/2500-2139-2020-13-3-307-315 · Cited by 1
Smekens, L., Genoud, V., Usdin, N., & Aïssa, A. B. (2023) · Praxis · doi:10.1024/1661-8157/a003976 · Cited by 1
Shi, Y., Dolan, M., Mastri, M., McKenery, A., Hill, J. W., Dommer, A. P., Benzekry, S., Long, M., Abrams, S. I., Puzanov, I. J., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.07.01.450417 · Cited by 1
Shannon, V. R., Eapen, G. A., Jiménez, C. A., Grosu, H. B., Morice, R. C., Bashoura, L., Sheshadre, A., Evans, S. E., Adachi, R., Kroll, M. H., et al. (2022) · Wiley eBooks · doi:10.1002/9781119000822.hfcm134.pub2 · Cited by 1
Checkpoint Inhibitor-Associated Autoimmunity: What a Rheumatologist Needs to Know.
Ghosh, N., & Bass, A. R. (2022) · PubMed · doi:10.1097/rhu.0000000000001209
Management of Immune Checkpoint Inhibitor-Related Rheumatological Toxicities
Fong, P. Y., Chow, S. C., Kwong, B. M. H., Lau, C. C. L., Lau, C. Y. C., Lee, A. H. T., Nip, H. Y., Wong, C. Y., Yan, B. T. H., & Chung, H. Y. (2020) · Journal of Clinical Rheumatology and Immunology · doi:10.1142/s2661341720300013
Critical Analysis of Immune Checkpoint Inhibitor Immunotoxicity Management
Lopes, C., Morgado, S., Plácido, A. I., Roque, F., & Morgado, M. (2021) · SN Comprehensive Clinical Medicine · doi:10.1007/s42399-020-00670-w
Cancer Immunotherapy in Patients with Preexisting Inflammatory Arthritis
Thanarajasingam, U., & Abdel‐Wahab, N. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_12
Management of Rheumatic Immune-Related Adverse Events (irAEs): General Principles
Meara, A. S., & Calabrese, L. H. (2021) · Springer eBooks · doi:10.1007/978-3-030-56824-5_14
Las formas precarias de tenencia y de trabajo de la tierra en la agricultura
Molina, O., & Aurelio, F. (1983) · Repositorio Institucional (Universidad de Cuenca)
(2019) · Reactions Weekly · doi:10.1007/s40278-019-59851-y
Kamal, M. J., Baudo, M., Joseph, J. J., Geng, Y., & Qdaisat, A. Z. (2022) · Reports — Medical Cases Images and Videos · doi:10.3390/reports5030031
Thomas, A. S., & Wang, Y. (2022) · Springer eBooks · doi:10.1007/978-3-031-00241-0_5
Diagnostic et traitement des complications neurologiques des immunothérapies anticancéreuses
Farina, A., & Joubert, B. (2023) · Pratique Neurologique - FMC · doi:10.1016/j.praneu.2023.01.011
Park, S. E. (2023) · Journal of Korean Medical Association · doi:10.5124/jkma.2023.66.2.116
Checkpoint Inhibitor-Induced Pneumonitis: Incidence and Management
Yuan, C., Gada, K. D., & Desai, A. G. (2023) · Current Pulmonology Reports · doi:10.1007/s13665-023-00314-z
Metadata
- Authors
- Stroud, C. R., Hegde, A., Cherry, C., Naqash, A. R., Sharma, N., Addepalli, S., Cherukuri, S., Parent, T., Hardin, J., & Walker, P.
- Affiliations
- East Carolina University (US)
- Corresponding author
- Hegde, Aparna
- Venue
- Journal of Oncology Pharmacy Practice
- Publisher
- SAGE Publications
- Published
- 2017-12-05
- Volume
- 25
- Issue
- 3
- Pages
- 551-557
- ISSN
- 1078-1552 (ISSN-L)
- 1477-092X
- OpenAlex
- W2771433910
- Cited by
- 331
- References
- 26
- Citations by year
- 2026: 25 · 2025: 28 · 2024: 43 · 2023: 45 · 2022: 55 · 2021: 46 · 2020: 58 · 2019: 22 · 2018: 7 · 2017: 1
- FWCI
- 10.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Oncology Pharmacy Practice (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Toxicology › Pharmacovigilance and Adverse Drug Reactions
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- tocilizumab, immune checkpoint inhibitors, immune-related adverse events, nivolumab, IL-6 receptor inhibitor, pneumonitis, serum sickness, C-reactive protein, lung cancer, hypophysitis, colitis, cerebritis, hypotension, hypoxemia
- MeSH terms
- Nivolumab, Adrenal Cortex Hormones, Adult, Aged, Aged, 80 and over, Female, Humans, Lung Neoplasms, Male, Middle Aged, Programmed Cell Death 1 Receptor, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
